Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults.

BNT162b2 SARS-CoV-2 antibody longevity humoral immunity vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
20 May 2022
Historique:
received: 12 04 2022
revised: 10 05 2022
accepted: 11 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Little is known about the longevity of antibodies after a third dose of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany). Therefore, serum antibody levels were evaluated after a third dose of BNT162b2 in healthy adult healthcare workers in Germany. These antibody levels dropped significantly within a short period of 11 weeks from 4155.59 ± 2373.65 BAU/mL to 2389.10 ± 1433.90 BAU/mL, p-value < 0.001 but remained higher than after the second dose (611.92 ± 450.31 BAU/mL). To evaluate the quality of the humoral immune response, we additionally measured neutralizing antibodies, which also showed a small but significant decrease within this short period. These data underline the positive effect of a third dose of BNT162b2 concerning antibody re-induction but also shows a drop of Anti-SARS-CoV-2-IgG within a short span of time.

Identifiants

pubmed: 35632564
pii: vaccines10050805
doi: 10.3390/vaccines10050805
pmc: PMC9145913
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Int J Infect Dis. 2021 Jan;102:136-143
pubmed: 33075538
J Infect. 2022 Jun;84(6):795-813
pubmed: 35405168
Clin Chem Lab Med. 2022 Mar 17;60(6):934-940
pubmed: 35303766
J Infect Dis. 2022 Jan 5;225(1):30-33
pubmed: 34726239
Kidney Int. 2021 Sep;100(3):702-704
pubmed: 34216675
Front Immunol. 2022 Mar 04;13:839922
pubmed: 35309303
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Transplantation. 2021 Nov 1;105(11):e267-e269
pubmed: 34342963
JAMA. 2021 Jul 23;:
pubmed: 34297036
Lancet Respir Med. 2022 Feb;10(2):e19
pubmed: 35030317
J Med Virol. 2022 Aug;94(8):3768-3775
pubmed: 35434796
J Hepatol. 2022 Apr 19;:
pubmed: 35452692
J Clin Virol. 2021 Nov;144:104984
pubmed: 34563863
Clin Infect Dis. 2021 May 4;72(9):1645-1648
pubmed: 32628750
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454

Auteurs

Jonas Herzberg (J)

Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, 21465 Reinbek, Germany.

Bastian Fischer (B)

Institut für Laboratoriums-und Transfusionsmedizin, Herz-und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.

Heiko Becher (H)

Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Ann-Kristin Becker (AK)

Abteilung für Psychiatrie und Psychotherapie, Asklepios Klinik Harburg, 21075 Hamburg, Germany.

Human Honarpisheh (H)

Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, 21465 Reinbek, Germany.

Salman Yousuf Guraya (SY)

Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.

Tim Strate (T)

Department of Surgery, Krankenhaus Reinbek St. Adolf-Stift, 21465 Reinbek, Germany.

Cornelius Knabbe (C)

Institut für Laboratoriums-und Transfusionsmedizin, Herz-und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.

Classifications MeSH